L-798106

• 产品号: L4545
• CAS号: 244101-02-8
• 分子式: C27H22BrNO4S
• 分子量: 536.43688
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: L-798106
• IUPAC标准名: N-(5-bromo-2-methoxybenzenesulfonyl)-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
• IUPAC传统名: N-(5-bromo-2-methoxybenzenesulfonyl)-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
• 别名: (2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide

产品登记号

• MDL号: MFCD08272644
• CAS号: 244101-02-8

产品性质

• Empirical Formula (Hill Notation): C27H22BrNO4S
• 纯度: ≥98% (HPLC)
• 外观: powder
• 溶解度: DMSO: >20 mg/mL
• GHS危险声明: H413
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.1

详细说明 (简体中文)

Biochem/physiol Actions
L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.1